TABLE 3.
Subanalysis among treated for the relationship between angiotensin receptor blocker subtype and lung cancer incidence
| Stratified by smoking statusa | HR for ARB (95% CI) | P |
| All current smokers | 0.72 (0.64–0.82) | <0.001 |
| All former smokers | 0.86 (0.70–1.07) | 0.175 |
| All never smoked | 0.42 (0.18–1.02) | 0.06 |
| Stratified ARB subtype in a cohort of all ARB usersb | HR for ARB subtype (95% CI) | P |
| Losartan | 1 (reference) | |
| Candesartan | 1.00 (0.67–1.51) | 0.79 |
| Irbesartan | 0.94 (0.73–1.22) | 0.95 |
| Valsartan | 0.94 (0.69–1.27) | 0.99 |
ARB, angiotensin receptor blocker; CI, confidence interval; HR, hazard ratio.
a
Adjusted for age, race, Hispanic ethnicity, diabetes mellitus and BMI.
b
Adjusted for age, race, Hispanic ethnicity, smoking status, diabetes mellitus and BMI for all patients.